RAND's divisions conduct research on a uniquely broad front for clients around the globe.
Most relevant regions
Research
Feb 1, 2012
Regional variation in Medicare Part D spending for prescription drugs results largely from differences in the cost of drugs selected rather than prescription volume.
The financial burden of prescription drugs has declined recently for the nonelderly. The decrease is probably due to increased use of generic drugs. The financial burden remains high among those with public insurance and those with low incomes.
Sep 1, 2011
A systematic review on the efficacy and safety of atypical antipsychotic medications for use in conditions lacking approval for labeling and marketing by the US Food and Drug Administration.
Research Summary
Jul 20, 2011
RxNorm has potential to improve how medications are represented in e-prescribing transactions.
Through laboratory research and pilot testing, the authors evaluated RxNorm's potential to improve how medications are represented in electronic prescribing (e-prescribing) transactions.
Mar 1, 2011
This paper presents findings from a study evaluating who may be using $4 programs and identifying potential national savings from broad use of these programs.
Jan 1, 2011
Doctor-patient communication is strongly associated with use of patient assistance programs; this link has important implications for clinical care regardless of whether the programs are viewed as drivers of prescription costs or a remedy for them.
Jan 1, 2010
This article uses matched survey and administrative data to estimate, as of 2006, the size of the population eligible for the Low-Income Subsidy (LIS), which was designed to provide "extra help" with premiums, deductibles, and copayments for Medicare Part D beneficiaries with low income and limited assets.
Oct 21, 2009
Describes the effects that prescription drug cost sharing has on drug spending, compliance with drug therapy, patient health, and overall health care costs.
Sep 23, 2009
Investigates two mechanisms by which governments may influence pharmaceutical research and development priorities: (1) public funding for life sciences research; and (2) prescription drug insurance, as in Medicare Part D.
Press
Aug 24, 2009
The program created to provide Medicare recipients with prescription drug benefits exceeded expectations during its first two years, extending pharmacy coverage to most seniors while reducing their overall spending on drugs.
Aug 1, 2009
Assess the broad impacts of Medicare Part D and the extent to which prior concerns have been realized.